( OTC-BB:SRNE, OTC-PINK:SRNE )

News from Sorrento Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 14, 2016, 07:00 ET Sorrento to Present at the 28th Annual ROTH Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated...


Mar 04, 2016, 07:00 ET Sorrento to Present at the Cowen and Company 36th Annual Health Care Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...


Jan 11, 2016, 07:00 ET Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


Jan 11, 2016, 06:00 ET Sorrento and Karolinska Institutet Establish Exclusive Partnership for Research and Development of Natural Killer Cell-based Therapies

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments...


Jan 08, 2016, 07:00 ET Upcoming Corporate Presentations In San Francisco

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...


Oct 19, 2015, 06:00 ET Sorrento Expands its Executive Management Team with Appointment of Dr. Jeffrey Su as Chief Operating Officer to Lead its in-house Bioprocess and Manufacturing Operations

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated pain,...


Oct 08, 2015, 19:00 ET Sorrento to Present at Aegis Capital Corporation 2015 Growth Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...


Sep 08, 2015, 13:30 ET Sorrento to Present at Upcoming Conferences

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), a clinical stage oncology company developing new treatments for cancer and...


May 18, 2015, 09:47 ET Sorrento gründet Tochtergesellschaft TNK Therapeutics mit Fokus auf zelluläre Immuntherapien

- Pipeline wird CAR.TNKs™'von der Stange' sowie komplementäre zelluläre und Immuntherapien umfassen  Sorrento Therapeutics, Inc. (NASDAQ: SRNE;...


May 18, 2015, 09:00 ET Sorrento richt dochterbedrijf TNK Therapeutics op dat zich zal focussen op cellulaire immunotherapieën

- Pijplijn bevat CAR.TNKs™ 'van de plank' evenals aanvullende cellulaire en immunotherapieën  Sorrento Therapeutics, Inc. (NASDAQ: SRNE;...


May 15, 2015, 16:26 ET NantWorks übernimmt Cynviloq™ für bis zu 1,3+ Milliarden USD

– Einstandszahlung in Höhe von 90+ Millionen USD und Meilensteinzahlungen von 1,2+ Milliarden USD – Sorrento behält Option für Mitentwicklung bzw....


May 15, 2015, 12:18 ET NantWorks acquiert Cynviloq™ pour un montant supérieur à 1,3 milliard de dollars US

-- Un versement initial de plus de 90 millions d'USD et des versements échelonnés de plus de 1,2 milliard d'USD --Sorrento garde la possibilité de...


May 15, 2015, 10:38 ET NantWorks verwerft Cynviloq™ voor minimaal $ 1,3 miljard

--Betaling van minimaal $ 90 miljoen vooraf en minimaal $ 1,2 miljard aan mijlpaalbetalingen --Sorrento behoudt optie voor de gezamenlijke...


May 04, 2015, 10:44 ET Sorrento gibt positive Ergebnisse für TRIBECA™ Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) freut sich, positive Ergebnisse der vor kurzem analysierten pharmakokinetischen (PK) Daten aus seiner...


May 04, 2015, 09:31 ET Sorrento kondigt een positief resultaat aan van het TRIBECA™-registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is verheugd met de bekendmaking van het positieve resultaat van de onlangs geanalyseerde...


May 04, 2015, 09:00 ET Sorrento Announces Positive TRIBECA™ Registrational Study Results

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive results from recently analyzed pharmacokinetic (PK) data from its...


Mar 17, 2015, 07:20 ET NantWorks et Sorrento annoncent une deuxième collaboration mondiale complète sur la découverte et le développement de nouvelles immunothérapies anticancéreuses

- NantCell acquiert les droits exclusifs d'anticorps comprenant les produits CAR-TNK™ et les inhibiteurs des points de contrôle PD-1 et...


Mar 17, 2015, 07:14 ET NantWorks en Sorrento kondigen tweede brede wereldwijde samenwerking aan in de ontdekking en ontwikkeling van nieuwe immunotherapieën tegen kanker

- NantCell zal exclusieve rechten verwerven op antilichamen waaronder CAR-TNK™ Producten en de checkpointremmers PD-1 en PD-L1  NantWorks,...


Mar 16, 2015, 13:56 ET NantWorks und Sorrento kündigen ihre zweite, umfassende, weltweite Kooperation bei der Entdeckung und Entwicklung neuartiger Immunotherapien gegen Krebs an

- NantCell erwirbt die exklusiven Rechte an Antikörpern, wie den CAR-TNK™ Produkten und den Checkpoint-Inhibitoren PD-1 und PD-L1  NantWorks,...


Mar 16, 2015, 09:00 ET NantWorks And Sorrento Announce Second Comprehensive Global Collaboration On Discovery And Development Of Novel Anti-Cancer Immunotherapies

 NantWorks, Inc. and Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that they have entered into a...